Urgent Notice for Altimmune Shareholders: Legal Rights and Deadlines Explained

Attention Altimmune Shareholders: Important Legal Notice

Altimmune, Inc. (NASDAQ: ALT) investors are urged to communicate with Levi & Korsinsky, LLP regarding their rights in response to a recent class action securities lawsuit. The firm is notifying shareholders about critical developments that could impact their investments. If you were a shareholder between August 10, 2023, and June 25, 2025, you might be eligible for recovery under this lawsuit.

Overview of the Lawsuit

The lawsuit was initiated to address concerns over alleged securities fraud that negatively affected shareholders. The central issue stems from a release by Altimmune on June 26, 2025, regarding the results of the IMPACT Phase 2b clinical trial for Pemvidutide, related to the treatment of MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease).

Notably, while the company had consistently projected optimistic results leading up to the announcement, the outcomes revealed a significant disappointment: the trial did not meet the statistical benchmarks for success, particularly concerning fibrosis reduction.

What Happened?

The trial results indicated a positive trend in fibrosis improvement. However, this was overshadowed by a higher-than-anticipated response from the placebo group. The defendants’ reactions to media inquiries showed a concerning indifference, attributing the lack of statistical significance to the trial's Phase 2 nature. They expressed hope for improved results in future Phase 3 analyses. Following this announcement, Altimmune's stock faced a dramatic decline, plummeting 53.2% from $7.71 per share to just $3.61 in a single day.

Who Should File a Claim?

If you experienced a financial loss during the specified period, you have until October 6, 2025, to petition the Court for lead plaintiff appointment. It is crucial to note that participants in the class action do not need to serve as lead plaintiffs to be part of any recovery.

Cost-Free Participation

Participating in this legal action poses no costs to investors. Class members may receive compensation without incurring any out-of-pocket expenses. There is no obligation to proceed with the lawsuit if you choose to engage Levi & Korsinsky.

Levi & Korsinsky’s Track Record

The last two decades have seen Levi & Korsinsky secure substantial recoveries for shareholders, winning high-profile cases backed by a team of over 70 proficient professionals. Recognized as one of the top firms for securities litigation, they consistently rank among the best in the field, according to ISS Securities Class Action Services.

Next Steps

For any shareholder seeking involvement or more information, you should reach out to the firm promptly. You can contact Joseph E. Levi at [email protected] or by phone at (212) 363-7500. Alternatively, more details can be found on their website at www.zlk.com.

Don’t wait until the deadline approaches; ensure your rights are protected. Time is of the essence, and engaging with experienced legal counsel could make a significant difference in the outcome for Altimmune investors.